By analysing MRI scans and a simple blood test from hundreds of patients, researchers identified patterns that reveal how ...

Objective Patients with atrial fibrillation (AF) frequently have multiple comorbidities that increase the risk of hospitalisation and contribute to higher mortality. However, studies examining the ...

In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...

The FDA approved nerandomilast (Jascayd) tablets for idiopathic pulmonary fibrosis (IPF), the first new product for the progressive lung condition in over a decade, the agency announced on Tuesday.

For the second year running, Pfizer has arrived at the European Society for Medical Oncology (ESMO) conference armed with data showing its one-time heart failure hopeful ponsegromab can treat a ...

The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds-those with high potency, selectivity, and favorable metabolic properties-at the earliest stages ...

AmgenNow offers evolocumab at a reduced price, bypassing insurer requirements, and supports the Trump administration's drug pricing efforts. The Most Favored Nation executive order aims to align US ...

In May 2025, the U.S. Army’s Soldier Lethality Project at the Picatinny Arsenal in New Jersey announced the official type classification of SIG Sauer’s M7 rifle and M250 automatic rifle, previously ...

Many drug trials are vetted by companies with ties to the drugmakers, raising concerns about conflicts of interest and patient safety. Credit...Blake Cale Supported by By Walt Bogdanich Carson Kessler ...

On September 16, 2025, the U.S. Food and Drug Administration (FDA) released more than 60 warning letters sent to specific pharmaceutical manufacturers, alleging misbranding of a particular drug ...

FDA leaders under President Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency's decisions from public ...